1 / 1

Antitumor Activity on Target Lesions: Comprehensive Response Rates Post-Crizotinib

This study evaluates the antitumor activity on target lesions in a group of 34 participants, showing a 65% overall response rate with complete, partial, stable, and progressive responses. The response rate post-crizotinib is 61%, and all treatment-naive patients showed a positive response. Presented at ESMO 2013, the results are based on the study by Camidge DR et al. (abstract 3401) and provide valuable insights into treatment outcomes.

garth
Download Presentation

Antitumor Activity on Target Lesions: Comprehensive Response Rates Post-Crizotinib

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CBNPC ALK+, activité antitumorale sur les lésions cibles (n = 34) Meilleure réponse globale Réponse complète Progression Stabilité Réponse partielle Taux de réponse : 65 % (22/34) [IC95 : 47-80] Post-crizotinib : 61 % (19/31) [incl. 1 criz intolérant] Naïf d’ITK : 100 % (3/3) [Incl. 1 CR] 40 20 0 -20 Variation des lésions cibles (%) -40 -60 -80 -100 • ESMO 2013 – D’après Camidge DR et al., abstr. 3401, actualisé

More Related